Ravulizumab versus Placebo in Adult Participants with Dermatomyositis.
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis. - Ravulizumab versus Placebo in Adult Participants with Dermatomyositis. A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Eval ...
Dermatomyositis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Ultomiris Product Name: Ravulizumab Product Code: [ALXN1210] INN or Proposed INN: RAVULIZUMAB Other descriptive name: ALXN1210 Trade Name: Ultomiris Product Name: Ravulizumab Product Code: [ALXN1210] INN or Proposed INN: RAVULIZUMAB Other descriptive name: ALXN1210 Trade Name: Nimenrix Product Name: Nimenrix Product Code: [NA] INN or Proposed INN: tetanus protein Other descriptive name: tetanus protein INN or Proposed INN: NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED WITH TETANUS TOXOID CARRIER PROTEIN Other descriptive name: NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED WITH TETANUS TOXOID CARRIER PROTEIN INN or Proposed INN: NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN Other descriptive name: NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETA Trade Name: Ultomiris Product Name: Ravulizumab Product Code: [ALXN1210] INN or Proposed INN: RAVULIZUM ...
ALEXION PHARMACEUTICALS INCORPORATED
NULL
Authorised-recruitment may be ongoing or finished
Female: yes Male: yes
180
Phase 2;Phase 3
France;United States;Spain;Germany;United Kingdom;Japan;Italy;Korea, Republic of